Internal Medicine, Rheumatology · Orlando, FL
NPI
1194907667
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
5750 Major Blvd Ste 150
Orlando, FL, 32819
Phone (407) 409-8118
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
149,343 services
Medicare patients, 2024
377
Average age 69
Drug cost, 2024
$4.7M
3,451 prescriptions
Company payments, 2025
$77K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Waleed A Bolad was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 68,800 times for 22 patients. In total Waleed A Bolad billed 149,343 services in 44 codes, and Medicare paid $1.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-01-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 68,800 | 22 | $3.59 | $247K |
| J3262 Injection, tocilizumab, 1 mg | Office | 26,277 | 11 | $4.13 | $108K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 16,780 | 22 | $8.89 | $149K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,500 | 11 | $33.90 | $288K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 3,061 | 32 | $0.10 | $298 |
| J0897 Injection, denosumab, 1 mg | Office | 2,400 | 25 | $20.59 | $49K |
| 99214 Office E&M - Established | Office | 774 | 328 | $101.28 | $78K |
| 96413 Chemotherapy Administration | Office | 403 | 68 | $96.65 | $39K |
| 96401 Chemotherapy Administration | Office | 396 | 52 | $53.88 | $21K |
| 96415 Chemotherapy Administration | Office | 125 | 15 | $21.86 | $2,732 |
| 96375 Injection Administration | Office | 86 | 16 | $12.48 | $1,073 |
| 99204 Office E&M - New | Office | 67 | 67 | $128.48 | $8,608 |
| 20611 Joint Injection | Office | 58 | 32 | $80.42 | $4,665 |
| J7323 Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | Office | 55 | 11 | $94.46 | $5,195 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 42 | 13 | $0.59 | $24.71 |
By year: 2022 $1.4M for 117,348 services; 2023 $1.4M for 119,041 services; 2024 $1.5M for 149,343 services.
Medicare prescription drug claims, 2024
In 2024, the drug Waleed A Bolad prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 388 prescriptions and refills. In total Waleed A Bolad wrote 3,451 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 388 | 641 | 188 | $9,051 |
| Prednisone Generic | 335 | 433 | 169 | $1,579 |
| Methotrexate Methotrexate Sodium | 305 | 424 | 149 | $4,293 |
| Gabapentin Generic | 167 | 203 | 71 | $1,935 |
| Pregabalin Generic | 125 | 133 | 55 | $3,323 |
| Leflunomide Generic | 120 | 194 | 64 | $5,216 |
| Benlysta Belimumab | 120 | 120 | 22 | $446K |
| Tramadol Hcl Generic | 116 | 116 | 58 | $917 |
| Enbrel Sureclick Etanercept | 88 | 88 | 26 | $643K |
| Mycophenolate Mofetil Generic | 82 | 116 | 39 | $13K |
| Folic Acid Generic | 82 | 138 | 43 | $401 |
| Tizanidine Hcl Generic | 82 | 100 | 45 | $767 |
| Duloxetine Hcl Generic | 79 | 129 | 37 | $993 |
| Azathioprine Generic | 75 | 106 | 35 | $1,436 |
| Acetaminophen-Codeine Acetaminophen With Codeine | 75 | 75 | 42 | $1,713 |
Brand drugs: 752 claims; generic drugs: 2,659 claims; opioid claims: 192.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Waleed A Bolad $77K ($77K in general payments such as food, travel and fees) from 23 companies. The largest payer was GlaxoSmithKline, LLC. with $25K.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 39 | $25K |
| Genzyme Corporation SNY | 21 | $22K |
| Mallinckrodt Hospital Products Inc. | 20 | $18K |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $7,983 |
| Amgen Inc. AMGN | 25 | $824 |
| Abbvie Inc. ABBV | 20 | $671 |
| UCB, Inc. UCB.BR | 24 | $593 |
| Novartis Pharmaceuticals Corporation NVS | 23 | $493 |
| Pfizer Inc. PFE | 32 | $341 |
| Janssen Biotech, Inc. JNJ | 8 | $271 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.